OnKure Therapeutics, Inc. (OKUR) - Total Liabilities
Based on the latest financial reports, OnKure Therapeutics, Inc. (OKUR) has total liabilities worth $7.25 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OKUR asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
OnKure Therapeutics, Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how OnKure Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see OnKure Therapeutics, Inc. total assets.
OnKure Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of OnKure Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Torimbia Socimi S.A.
MC:YTRM
|
Spain | €89.87 Million |
|
Technos S.A
SA:TECN3
|
Brazil | R$273.99 Million |
|
Haesung Industrial Co. Ltd
KQ:034810
|
Korea | ₩1.30 Trillion |
|
DMS Propertindo Tbk PT
JK:KOTA
|
Indonesia | Rp471.84 Billion |
|
The Pinkfong Company
KQ:403850
|
Korea | ₩22.39 Billion |
|
China National Accord Medicines Corp Ltd
SHE:200028
|
China | HK$27.21 Billion |
|
Bellevue Group AG
SW:BBN
|
Switzerland | CHF34.51 Million |
|
WMG Holdings Bhd
KLSE:6378
|
Malaysia | RM162.50 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down OnKure Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See OKUR net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OnKure Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OnKure Therapeutics, Inc. (2020–2025)
The table below shows the annual total liabilities of OnKure Therapeutics, Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.93 Million | -46.45% |
| 2024-12-31 | $11.08 Million | -91.95% |
| 2023-12-31 | $137.58 Million | +95.37% |
| 2022-12-31 | $70.42 Million | +933.57% |
| 2021-12-31 | $6.81 Million | -93.00% |
| 2020-12-31 | $97.34 Million | -- |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatmen… Read more